Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis—a post-hoc analysis of pooled data from three phase 3 trials with secukinumab

Abstract Objectives Our aims were to determine if the Psoriasis Area Severity Index (PASI) score and serum urate (SU) levels were associated at baseline and whether the change in PASI score during 12 weeks of treatment resulted in a significant change in SU, adjusted for relevant confounders. Method...

Full description

Saved in:
Bibliographic Details
Published in:Rheumatology advances in practice 2021-01, Vol.5 (1), p.rkab009-rkab009
Main Authors: Dehlin, Mats, Fasth, Andreas E R, Reinhardt, Maximilian, Jacobsson, Lennart T H
Format: Article
Language:English
Subjects:
Arthritis
Diuretics
gout
hyperuricaemia
inflammatory response
Medical research
Medicine, Experimental
Original
plaque psoriasis
Product development
Psoriasis
Reumatologi och inflammation
Rheumatology
Rheumatology and Autoimmunity
Risk factors
Skin
Type 2 diabetes
urate
uric-acid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objectives Our aims were to determine if the Psoriasis Area Severity Index (PASI) score and serum urate (SU) levels were associated at baseline and whether the change in PASI score during 12 weeks of treatment resulted in a significant change in SU, adjusted for relevant confounders. Methods Data from patients with psoriasis/PsA (n = 1042/204) in three phase 3 randomized control trials treated with secukinumab (dose 300 mg, n = 628) or placebo (n = 414) were pooled. At baseline, values for SU, PASI and the following covariates were assessed: age, sex, BMI, estimated glomerular filtration rate, and medication with diuretics. To assess the changes in PASI (ΔPASI) and SU (Δurate), the differences (week 12 minus baseline) in patients receiving the active drug were used. Multivariable linear regression, adjusting for covariates, was used to assess the association between PASI and SU at baseline with all patients pooled and to assess the association between Δurate and ΔPASI over 12 weeks of treatment with secukinumab. Results The degree of skin involvement of psoriasis showed a statistically significant, albeit modest, association with SU (R2 = 0.014, P 
ISSN:2514-1775
2514-1775
DOI:10.1093/rap/rkab009